Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
نویسندگان
چکیده
منابع مشابه
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
10-74 David Badesch, MD Dr. Badesch has received honoraria for service on steering committees or advisory boards (or as a consultant) to the following companies working in the area of pulmonary hypertension: Actelion/CoTherix, Gilead/Myogen, Encysive, Pfizer, Mondo-Biotech/Mondogen, Biogen IDEC, United Therapeutics/Lung Rx, GlaxoSmithKline, Lilly/ICOS, Bayer, Ikaria, and Arena. He has received ...
متن کاملPharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.
OBJECTIVE Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence. METHODS This guideline was based on systematic reviews of English language evidence published between 1990...
متن کاملSyncope in adults with pulmonary arterial hypertension.
OBJECTIVES The aim of this study was to determine the prognostic significance of syncope in pulmonary arterial hypertension (PAH). BACKGROUND Some patients with PAH have a history of syncope at presentation. The prognostic implications of syncope in PAH have not yet been well characterized. METHODS This was a single-center cohort study of 378 patients with PAH seen at a dedicated pulmonary ...
متن کاملBeraprost therapy for pulmonary arterial hypertension.
OBJECTIVES The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analogue beraprost sodium during a 12-month double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH). BACKGROUND Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart failure and death. Despite the risks from...
متن کاملBosentan therapy for pulmonary arterial hypertension.
BACKGROUND Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chest
سال: 2014
ISSN: 0012-3692
DOI: 10.1378/chest.14-0793